FdaApplication
BLA 761363
Identifiers
- fda_app_no: BLA761363
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 2024-03-26 |
Revenue by product
WINREVAIR
| Period | Revenue |
|---|---|
| Q2 2026 | $588.0M |
| Q1 2026 | $525.0M |
| Q4 2025 | $467.0M |
| Q3 2025 | $360.0M |
| Q2 2025 | $336.0M |
| Q1 2025 | $280.0M |
| Q4 2024 | $200.0M |
| Q3 2024 | $149.0M |
| Q2 2024 | $70.0M |
| Q1 2024 | $0.0M |
| Q4 2023 | $0.0M |
| Q3 2023 | $0.0M |
| Q2 2023 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| WINREVAIR | SOTATERCEPT-CSRK | 60MG | For Injection |
| WINREVAIR | SOTATERCEPT-CSRK | 45MG | For Injection |
2 products